Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 4/20 | 0.40 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.36 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16946017 | 0.86 | TRPV1 (0.55) | TRPM8KCNA5EPHX1TRPV1 | |
| SCHEMBL4301160 | 0.80 | TRPM8 (0.46) | TRPM8KCNA5EPHX1TRPV1ALDH1A1 | |
| SCHEMBL1542834 | 0.80 | P2RX4 (0.44) | TRPM8KCNA5EPHX1TRPV1ALDH1A1 | |
| SCHEMBL31752406 | 0.75 | TRPM8 (0.46) | TRPM8KCNA5EPHX1TRPV1ALDH1A1 | |
| SCHEMBL5718187 | 0.74 | EPHX1 (0.51) | TRPM8KCNA5EPHX1TRPV1ALDH1A1 | |
| SCHEMBL27749439 | 0.73 | TRPM8 (0.35) | TRPM8TRPV1ALDH1A1HPGDMAPT | |
| SCHEMBL18259085 | 0.71 | CNR1 (0.36) | TRPM8EPHX1HPGD | |
| SCHEMBL18192793 | 0.71 | CNR1 (0.36) | TRPM8EPHX1HPGD | |
| SCHEMBL18192796 | 0.71 | CNR1 (0.36) | TRPM8EPHX1HPGD | |
| SCHEMBL30835092 | 0.70 | TRPM8 (0.50) | TRPM8KCNA5EPHX1TRPV1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8911715-B2 | L-menthyl-N-(2-hydroxyphenyl)carbamate | SYMRISE AG (DE) | 2014-12-16 | — | — | US | disclosed |
| US-20110129432-A1 | L-MENTHYL-N-(2-HYDROXYPHENYL)CARBAMATE | SYMRISE AG (DE) | 2011-06-02 | — | — | US | disclosed |
| EP-2307357-A1 | L-MENTHYL-N-(2-HYDROXYPHENYL)CARBAMATE | Symrise AG (DE) | 2011-04-13 | — | — | EP | disclosed |
| WO-2009144179-A1 | L-MENTHYL-N-(2-HYDROXYPHENYL)CARBAMATE | SYMRISE GMBH & CO. KG (DE) | 2009-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110129432-A1 | L-MENTHYL-N-(2-HYDROXYPHENYL)CARBAMATE | CRAT, LANCL1, ACAT1 | TRPM8 895/4885KCNA5 2305/4885EPHX1 487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.